Metal organic framework material as well as preparation method and application thereof

Abstract

The invention discloses a metal organic framework material and a preparation method and application thereof.The preparation method comprises the following preparation steps that zinc acetate and phycocyanin are dissolved in water, and a mixed solution is prepared; adding the mixed solution into a 2-methylimidazole aqueous solution, mixing and stirring, centrifuging, taking precipitate, washing with water, and dispersing in water to prepare a nano-particle dispersion liquid; and adding the nanoparticle dispersion liquid, epigallocatechin gallate and manganese chloride into water, mixing, stirring, centrifuging, taking precipitate, washing with water, and dispersing in water to obtain the metal organic framework material. The metal organic framework material prepared by the invention has free radical scavenging and anti-oxidation capabilities; the traditional Chinese medicine composition has an anti-inflammatory effect, can relieve liver injury and necrosis, and is suitable for treating acute liver injury; the compound also has the effects of regulating inflammatory response, promoting macrophage transformation and inhibiting T cell activation, and is suitable for immune regulation and control.

Description

Technical Field

[0001] The present invention relates to the technical field of metal organic frameworks, and in particular to a metal organic framework material, a preparation method thereof, and an application thereof. Background Art

[0002] Acute liver injury (ALI) refers to a clinical condition in which patients without liver disease or with stable liver disease experience a rapid deterioration of liver function within a short period of time after exposure to liver-damaging factors (such as drugs, toxins, and infections). Its primary pathological manifestation is severe damage to liver function and structure, stemming from a violent outbreak of reactive oxygen species (ROS) in hepatocytes. This increase in ROS leads to oxidative stress in hepatocytes, which in turn triggers lipid peroxidation, protein denaturation, and DNA damage in cell membranes, ultimately leading to hepatocyte necrosis and apoptosis. Treatment for ALI primarily involves discontinuation of suspected liver-damaging medications, liver protection, anti-inflammatory, and antioxidant therapies.

[0003] Due to their unique physicochemical properties, such as small size, high specific surface area, and good biocompatibility, nanomedicines can selectively accumulate in the liver, promote targeted therapeutic intervention, and show broad prospects in the treatment of ALI. Summary of the Invention

[0004] The purpose of the present invention is to avoid the shortcomings of the existing technology and provide a metal-organic framework material and its preparation method and application. Phycocyanin is encapsulated with zinc acetate and then mixed with epigallocatechin gallate and manganese chloride to prepare the metal-organic framework material. The prepared metal-organic framework material has good stability and is suitable for in vitro antioxidant, treatment of acute liver injury, and immune regulation.

[0005] To achieve the above object, the present invention provides a method for preparing a metal organic framework material, comprising the following steps:

[0006] Dissolving zinc acetate and phycocyanin in water to prepare a mixed solution;

[0007] The mixed solution is added to a 2-methylimidazole aqueous solution, mixed and stirred, centrifuged, the precipitate is washed with water, and dispersed in water to obtain a nanoparticle dispersion;

[0008] The nanoparticle dispersion, epigallocatechin gallate and manganese chloride are added into water, mixed and stirred, centrifuged, and the precipitate is washed with water and dispersed in water to prepare a metal organic framework material.

[0009] Furthermore, the mass ratio of zinc acetate to phycocyanin is 5:1-2.

[0010] Furthermore, the mass ratio of the phycocyanin to 2-methylimidazole is 1-2:0.2.

[0011] Furthermore, the concentration of the 2-methylimidazole aqueous solution is 90-110 mg / mL.

[0012] Furthermore, the mass ratio of the epigallocatechin gallate to the manganese chloride is 2-3:1.

[0013] The present invention also provides a metal organic framework material, which is prepared by the above-mentioned preparation method of the metal organic framework material.

[0014] The present invention also provides an application of a metal organic framework material. The metal organic framework material is used for in vitro anti-oxidation.

[0015] The present invention also provides an application of a metal-organic framework material. The metal-organic framework material is used for treating acute liver injury.

[0016] The present invention also provides an application of a metal organic framework material, wherein the metal organic framework material is used for immune regulation.

[0017] Beneficial effects of the method for preparing a metal organic framework material of the present invention:

[0018] The present invention prepares a metal-organic framework material through a simple method. The metal-organic framework material has high stability, is not easily decomposed, and is suitable for biomedicine; has excellent free radical scavenging and antioxidant properties, and is suitable for in vitro antioxidant applications; in the event of liver damage, it can reduce apoptosis of liver tissue cells, alleviate liver tissue damage and death, and exhibit excellent anti-inflammatory ability, and is suitable for the treatment of acute liver injury; in addition, the metal-organic framework material can also promote macrophage M1-M2 conversion, inhibit the maturation of dendritic cells, block the transmission of antigens, and inhibit the activation of T cells, and can be used in immune regulation. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Example 1 Transmission electron microscopy image and HAADF spectrum of PC-Mn@EGCG; scale bar = 200 nm;

[0020] Figure 2 Example 1 Zeta potential diagram of PC-Mn@EGCG;

[0021] Figure 3 Example 4 Free radical scavenging ability of PC-Mn@EGCG;

[0022] Figure 4 Example 4 ESR spectrum of PC-Mn@EGCG capturing free radical adduct;

[0023] Figure 5Example 5 Results of ALT and AST in mouse serum; n=6; *p<0.05, **p<0.01, ****p<0.0001;

[0024] Figure 6 Example 5: Typical images of H&E staining and statistical results of hepatocyte necrosis area; n=4; ****p<0.0001, scale bar=100 μm;

[0025] Figure 7 Example 5 ELISA method for detecting the levels of inflammatory factors in mouse serum; n = 6; **p < 0.01, ***p < 0.001, ****p < 0.0001;

[0026] Figure 8 Example 6 qRT-PCR detection of inflammatory and anti-inflammatory factors in mouse liver; n = 3-6; *p < 0.05, **p < 0.01, ***p < 0.001;

[0027] Figure 9 Example 6 Results and statistics of flow cytometry analysis; **p<0.01, ***p<0.001, ****p<0.0001. DETAILED DESCRIPTION

[0028] The preferred embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. Although preferred embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments described herein. Rather, these embodiments are provided to make the present invention more thorough and complete and to fully convey the scope of the present invention to those skilled in the art.

[0029] The present application provides a method for preparing a metal-organic framework material, comprising:

[0030] Dissolve zinc acetate and phycocyanin in water at a mass ratio of 5:1-2 to prepare a mixed solution;

[0031] The mixed solution was added to a 90-110 mg / mL 2-methylimidazole aqueous solution, mixed and stirred, centrifuged, the precipitate was washed with water, and dispersed in water to obtain a nanoparticle dispersion; the mass ratio of the phycocyanin to the 2-methylimidazole was 1-2:0.2;

[0032] The nanoparticle dispersion, epigallocatechin gallate, and manganese chloride are added to water, mixed and stirred, centrifuged, the precipitate is washed with water, and dispersed in water to prepare a metal-organic framework material; the mass ratio of the epigallocatechin gallate to the manganese chloride is 2-3:1;

[0033] The present application also provides a metal-organic framework material prepared by the above method. The metal-organic framework material has an electrokinetic potential value of less than -30mV and has good stability, and can be used for in vitro anti-oxidation, treatment of acute liver injury and immune regulation of the body.

[0034] Example 1 Preparation of Metal-Organic Framework Materials

[0035] S1: Weigh 10 mg of zinc acetate and 3 mg of phycocyanin and dissolve them in 6 mL of water to prepare a mixed solution;

[0036] In this embodiment, the mass ratio of zinc acetate to phycocyanin is 10:3;

[0037] S2: During the stirring process, the mixed solution was added to the 2-methylimidazole aqueous solution, and the stirring was continued for 50 minutes. The mixture was centrifuged at 5000 relative centrifugal force (RCF) for 10 minutes to collect the precipitate; the precipitate was dissolved in 5 mL of pure water, centrifuged at 5000 RCF for 10 minutes, and washed with water three times; the precipitate was dissolved in 10 mL of water to obtain a nanoparticle dispersion;

[0038] In this embodiment, the mass ratio of phycocyanin to 2-methylimidazole is 3:0.4;

[0039] In this embodiment, the concentration of the 2-methylimidazole aqueous solution is 100 mg / mL, and the preparation method is as follows: weigh 400 mg of 2-methylimidazole and dissolve it in 4 mL of water;

[0040] S3: 1 mL of the nanoparticle dispersion was added to 2 mL of water and 1 mL of epigallocatechin gallate (EGCG), and 100 μL of manganese chloride (10 mg / mL) (2.5 mg / mL) was added and stirred for 5 min; the mixture was centrifuged, and the precipitate was washed three times with water and dissolved in 5 mL of water to prepare the metal-organic framework material (PC-Mn@EGCG);

[0041] In this embodiment, the mass ratio of the epigallocatechin gallate to the manganese chloride is 2.5:1.

[0042] The PC-Mn@EGCG prepared in Example 1 was subjected to transmission electron microscopy (TEM) and high-angle annular dark field imaging (HAADF) spectroscopic analysis:

[0043] like Figure 1As shown in the figure, the TEM image of PC-Mn@EGCG prepared in Example 1 shows the morphology of PC-Mn@EGCG; the HAADF spectrum analysis of the distribution of each element in PC-Mn@EGCG shows that the distribution of C (red), N (green), O (blue), Mn (yellow) and Zn (orange) elements in PC-Mn@EGCG in the HAADF spectrum is consistent with the morphology shown in the TEM image of PC-Mn@EGCG, and each element is uniformly distributed in the PC-Mn@EGCG morphology. This shows that PC-Mn@EGCG was successfully constructed.

[0044] Stability test of PC-Mn@EGCG prepared in Example 1:

[0045] like Figure 2 As shown, the zeta potential (Zeta) plot of PC-Mn@EGCG shows a single peak at -30.43 mV on the horizontal axis, demonstrating a normal distribution, indicating a zeta potential of -30.43 mV. The larger the zeta potential, the stronger the repulsive force between the particles and the greater the stability of the system. The PC-Mn@EGCG prepared in this example has an absolute zeta potential of 30.43 mV, demonstrating excellent stability and promising biomedical applications.

[0046] Example 2 Preparation of Metal-Organic Framework Materials

[0047] S1: Weigh 10 mg of zinc acetate and 2 mg of phycocyanin and dissolve them in 6 mL of water to prepare a mixed solution;

[0048] In this embodiment, the mass ratio of zinc acetate to phycocyanin is 5:1

[0049] S2: During the stirring process, the mixed solution was added to the 2-methylimidazole aqueous solution, and the stirring was continued for 50 minutes. The mixture was centrifuged at 5000 relative centrifugal force (RCF) for 10 minutes to collect the precipitate; the precipitate was dissolved in 5 mL of pure water, centrifuged at 5000 RCF for 10 minutes, and washed with water three times; the precipitate was dissolved in 10 mL of water to obtain a nanoparticle dispersion;

[0050] In this embodiment, the mass ratio of phycocyanin to 2-methylimidazole is 1:0.2;

[0051] In this embodiment, the mass ratio of zinc acetate, phycocyanin and 2-methylimidazole is 10:2:0.4;

[0052] In this embodiment, the concentration of the 2-methylimidazole aqueous solution is 90 mg / mL, and the preparation method is as follows: weigh 400 mg of 2-methylimidazole and dissolve it in 4 mL of water;

[0053] S3: 1 mL of the nanoparticle dispersion was added to 2 mL of water and 1 mL of epigallocatechin gallate (EGCG) (2 mg / mL), and 100 μL of manganese chloride (10 mg / mL) was added. The mixture was stirred for 5 min and centrifuged. The precipitate was washed three times with water and dissolved in 5 mL of water to obtain the metal-organic framework (PC-Mn@EGCG).

[0054] In this embodiment, the mass ratio of the epigallocatechin gallate to the manganese chloride is 2:1.

[0055] Example 3 Preparation of Metal-Organic Framework Materials

[0056] S1: Weigh 10 mg of zinc acetate and 4 mg of phycocyanin and dissolve them in 6 mL of water to prepare a mixed solution;

[0057] In this embodiment, the mass ratio of zinc acetate to phycocyanin is 5:2

[0058] S2: During the stirring process, the mixed solution was added to the 2-methylimidazole aqueous solution, and the stirring was continued for 50 minutes. The mixture was centrifuged at 5000 relative centrifugal force (RCF) for 10 minutes to collect the precipitate; the precipitate was dissolved in 5 mL of pure water, centrifuged at 5000 RCF for 10 minutes, and washed with water three times; the precipitate was dissolved in 10 mL of water to obtain a nanoparticle dispersion;

[0059] In this embodiment, the mass ratio of phycocyanin to 2-methylimidazole is 1:0.1;

[0060] In this embodiment, the concentration of the 2-methylimidazole aqueous solution is 100 mg / mL, and the preparation method is as follows: weigh 400 mg of 2-methylimidazole and dissolve it in 4 mL of water;

[0061] S3: 1 mL of the nanoparticle dispersion was added to 2 mL of water and 1 mL of epigallocatechin gallate (EGCG) (3 mg / mL), and 100 μL of manganese chloride (10 mg / mL) was added. The mixture was stirred for 5 min and centrifuged. The precipitate was washed three times with water and dissolved in 5 mL of water to obtain the metal-organic framework (PC-Mn@EGCG).

[0062] In this embodiment, the mass ratio of the epigallocatechin gallate to the manganese chloride is 3:1.

[0063] Example 4 PC-Mn@EGCG is used for in vitro antioxidant

[0064] The PC-Mn@EGCG prepared in Example 1 was prepared into solutions with concentrations of 10 μg / mL, 20 μg / mL, 40 μg / mL, 80 μg / mL, 120 μg / mL, and 160 μg / mL. The scavenging rates of PC-Mn@EGCG at different concentrations on ABTS free radicals were calculated. The results are as follows: Figure 3 A. The scavenging rate of DPPH free radicals by PC-Mn@EGCG at different concentrations was calculated. The results are shown in Figure 3 As shown in B, the effects of different concentrations of PC-Mn@EGCG on superoxide anions (O2 - ) free radical scavenging rate, the results are as follows Figure 3 As shown in C.

[0065] Combine Figure 3 It can be seen that PC-Mn@EGCG can effectively scavenge ABTS free radicals in a concentration-dependent manner. Specifically, as the concentration of PC-Mn@EGCG increases, the ABTS scavenging rate increases. When the concentration of PC-Mn@EGCG increases from 20 μg / mL to 160 μg / mL, the ABTS elimination rate rapidly increases from 14% to 83%.

[0066] Similarly, when the concentration of PC-Mn@EGCG reached 160 μg / mL, the DPPH clearance rate also reached 35%, showing obvious concentration dependence.

[0067] In addition, PC-Mn@EGCG has a strong affinity for superoxide anions (O2 - ) free radicals also showed excellent scavenging effect, with a scavenging rate of up to 75% at a concentration of 10 μg / mL. These results fully demonstrate that PC-Mn@EGCG has excellent and rapid free radical scavenging ability.

[0068] In order to further verify the antioxidant properties of PC-Mn@EGCG, this example uses electron spin resonance (ESR) technology to capture hydroxyl radicals (·OH), superoxide anions (O2 - ) adducts and DPPH free radicals. The signal intensity and peak area in the ESR spectrum are proportional to the free radical concentration. Therefore, the quantitative analysis of free radicals can be achieved by observing the integrated peak area. Specifically, the stronger the signal and the larger the peak area, the more free radicals there are. Figure 4 As shown in the spectrum of this embodiment, after adding PC-Mn@EGCG, the hydroxyl radicals (·OH) and superoxide anions (O2 - ) adducts and DPPH radical signals are marked in red.

[0069] like Figure 4As shown in Figure A, in the presence of PC-Mn@EGCG, the ESR signal peak of hydroxyl radical (·OH) is significantly reduced, which intuitively reflects the efficient scavenging ability of PC-Mn@EGCG for ·OH. Figure 4 As shown in B, with the addition of PC-Mn@EGCG, the O2· - The peak intensity of the adduct also weakened, which indicated that O2· - The adduct is effectively consumed. Figure 4 As shown in Figure C, under the action of PC-Mn@EGCG, the ESR signal peak of DPPH· also showed a significant decrease, further confirming the excellent scavenging ability of PC-Mn@EGCG for DPPH·.

[0070] In summary, the PC-Mn@EGCG in this example exhibited excellent multiple antioxidant properties in scavenging various free radicals in vitro and can be used for in vitro antioxidant activities.

[0071] Example 5 PC-Mn@EGCG for the treatment of acute liver injury

[0072] Blank control group: mice were not induced by APAP and were not given PC-Mn@EGCG. Figure 5 As shown in the first column (indicated by APAP- and PC-Mn@EGCG- in the accompanying figures);

[0073] Induction control group: mice were induced with APAP and not administered with PC-Mn@EGCG. Figure 5 As shown in the second column (indicated by APAP+ and PC-Mn@EGCG- in the accompanying figures);

[0074] Drug-administered experimental group: mice were induced with APAP and then administered with PC-Mn@EGCG. Figure 5 As shown in the third column (indicated by APAP+ and PC-Mn@EGCG+ in the figure); the concentration of PC-Mn@EGCG is 160 μg / mL.

[0075] To investigate the therapeutic effects of PC-Mn@EGCG on acute liver injury (ALI), an APAP-induced mouse model of acute liver injury was established. During the course of acute liver injury, serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) increase significantly. Therefore, ALT and AST can be used to assess liver health and function.

[0076] The results are as follows Figure 5As shown, the serum ALT and AST levels of mice in the blank control group remained low, while those in the induced control group increased significantly, indicating that APAP successfully induced severe liver damage. Conversely, compared with the control group, transaminase (ALT, AST) levels in mice administered PC-Mn@EGCG were significantly reduced. These results demonstrate that PC-Mn@EGCG can effectively improve APAP-induced abnormal transaminase (ALT, AST) levels in mice, thereby alleviating acute liver injury.

[0077] To further explore the protective effect of PC-Mn@EGCG on ALI, this example carried out pathological evaluation of the liver tissues of the three experimental groups of mice. The liver tissue structure was observed by H&E staining to visually evaluate the liver health of the mice. The results are as follows: Figure 6 shown.

[0078] Figure 6 As shown in Figure A, the liver tissue structure of the blank control group remained intact, with no obvious damage. The liver tissue structure of the mice in the induced control group was loose, with blurred cell outlines and obvious areas of tissue necrosis (marked with dotted lines in the figure), indicating significant cell damage. After treatment with PC-Mn@EGCG, the liver cell outlines of the mice in the experimental group were relatively clear, and the area of ​​liver necrosis was significantly reduced compared to the induced control group. Figure 6 Figure B also shows that the apoptotic area of ​​the induced control group was abnormally increased compared with the blank control group. After treatment with PC-Mn@EGCG, the apoptotic area of ​​the experimental group was significantly reduced, indicating that PC-Mn@EGCG can effectively alleviate liver tissue damage and necrosis in acute liver injury.

[0079] Based on the above results, PC-Mn@EGCG showed a significant protective effect in the APAP-induced acute liver injury model and played a therapeutic role in liver damage.

[0080] In order to further evaluate the anti-inflammatory ability of PC-Mn@EGCG in vivo, the content of inflammatory factors (IL-6, TNF-α, MCP-1 and IL-1β) in mouse serum and liver was detected by enzyme-linked immunosorbent assay (ELISA) to evaluate the inflammatory response in mouse serum. Figure 7 shown.

[0081] Figure 7As can be seen, the serum levels of IL-6, TNF-α, MCP-1, and IL-1β in the healthy mice in the blank control group were all at extremely low levels. After APAP induction, the inflammatory factors (IL-6, TNF-α, MCP-1, and IL-1β) in the serum of the mice in the induced control group increased abnormally. After PC-Mn@EGCG administration, the inflammatory factors in the serum of the experimental group mice decreased significantly. This proves that PC-Mn@EGCG can inhibit the inflammatory response of the mouse liver, thereby exerting a hepatoprotective effect.

[0082] Example 6 PC-Mn@EGCG for immune regulation

[0083] Blank control group: mice were not induced by APAP and were not given PC-Mn@EGCG. Figure 5 As shown in the first column (indicated by APAP- and PC-Mn@EGCG- in the accompanying figures);

[0084] Induction control group: mice were induced with APAP and not administered with PC-Mn@EGCG. Figure 5 As shown in the second column (indicated by APAP+ and PC-Mn@EGCG- in the accompanying figures);

[0085] Drug-administered experimental group: mice were induced with APAP and then administered with PC-Mn@EGCG. Figure 5 As shown in the third column (indicated by APAP+ and PC-Mn@EGCG+ in the figure); the concentration of PC-Mn@EGCG is 160 μg / mL.

[0086] The mRNA expression levels of pro-inflammatory factors (IL-6, TNF-α, MCP-1 and IL-1β) and anti-inflammatory factor (CD206) in the mouse liver were detected.

[0087] The results are as follows Figure 8 As shown in the results, at the mRNA level, APAP significantly increased the expression of IL-6, TNF-α, and IL-1β compared with the blank control group, while PC-Mn@EGCG administration reduced the expression levels of the above pro-inflammatory cytokines in the liver.

[0088] Furthermore, APAP treatment significantly decreased the expression of an anti-inflammatory factor (CD206) in the liver of mice compared to the blank control group. However, after PC-Mn@EGCG treatment, CD206 expression levels significantly rebounded. These results suggest that PC-Mn@EGCG effectively regulates inflammatory responses by inhibiting the expression of pro-inflammatory factors and promoting the production of anti-inflammatory factors.

[0089] In order to study the immune effect in vivo, in this example, mice in the blank control group, induced control group and drug administration experimental group were euthanized, spleen cells were extracted, and immune cell analysis was performed using flow cytometry. When ALI occurs, the body is able to recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). The recognition of these molecular patterns triggers a series of inflammatory responses, leading to the recruitment and activation of macrophages in the liver, promoting the M1-M2 conversion of the macrophage phenotype, and then initiating an inflammatory response. Therefore, in this example, the phenotype of macrophages was marked, and immunofluorescence staining was performed using CD86 (a marker of M1 macrophages). As shown in 9A-B, the expression of CD86 in the spleen of mice in the blank control group was low, the expression of CD86 in the induced control group mice treated with APAP was increased, and the expression of CD86 in the drug administration experimental group mice decreased after treatment with PC-Mn@EGCG. These results indicate that PC-Mn@EGCG can inhibit the expression of M1 macrophages in the spleen of mice with liver injury and promote the transformation of M1 macrophages.

[0090] In addition, T cells are divided into CD4 + (helper T cells) and CD8 + (Cytotoxic T cells) have two core subtypes, of which CD8 + T cells express CD8 co-receptors on their surface, and initial CD8 + T cells are activated by antigen presentation by dendritic cells (DCs) to differentiate into effector cytotoxic T cells (CTLs) or memory T cells. CTLs maintain the body's defense balance through direct killing and immune regulation. Therefore, the maturation of dendritic cells can be measured by the expression levels of CD4 and CD8. Specifically, when the expression of CD4 and CD8 increases, the number of mature dendritic cells also increases.

[0091] like Figure 9 In CF and blank control mice, CD4 and CD8 expression was at low levels. In the induced control mice treated with APAP, CD4 and CD8 expression increased. After treatment with PC-Mn@EGCG, CD4 and CD8 expression in the experimental group decreased. This indicates that when mice are exposed to APAP, mature DCs increase in the body. Administration of PC-Mn@EGCG inhibits the maturation of DC cells, placing them in an immature state of immune tolerance. These immune-tolerant DCs are called tolerant DCs (tDCs), and they are able to suppress excessive immune activation in APAP mice.

[0092] As professional antigen-presenting cells, DCs constitutively express CD80 or highly express it upon activation. Some activated T cells also express CD80, demonstrating that CD80 is an important immune co-stimulatory molecule. Therefore, the expression levels of CD80 and CD86 can reflect the degree of T cell activation. NKp46, belonging to the immunoglobulin superfamily, can also be used to reflect the degree of immune activation through the expression levels of NKp46 and Gr1.

[0093] Figure 9 As shown in Figure GH, the expression levels of CD80 and CD86 in the treatment group were lower than those in the induction control group, indicating that PC-Mn@EGCG reduced the expression of CD80 and CD86, reduced T cell co-stimulatory signals, and thus inhibited T cell activation and proliferation, helping to control excessive immune responses. Similarly, the expression levels of NKP46 and Gr1 in the treatment group were lower than those in the induction control group, indicating that PC-Mn@EGCG can also inhibit the expression of NKP46 and Gr1, further suppressing excessive activation of the immune system.

[0094] In summary, PC-Mn@EGCG can regulate the inflammatory response in APAP-treated mice, promote the transformation of M1 macrophages, inhibit the activation of dendritic cells, and suppress the overactivation of the immune system. Therefore, PC-Mn@EGCG is suitable for immune regulation.

[0095] It is understandable that the above embodiments only express the preferred implementation modes of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the patent scope of the present invention. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present invention, the above technical features can be freely combined, and several deformations and improvements can be made, all of which fall within the scope of protection of the present invention. Therefore, all equivalent changes and modifications made to the scope of the claims of the present invention should fall within the scope of coverage of the claims of the present invention.

Claims

1. A method for preparing a metal organic framework material, characterized in that: The following steps are involved: Dissolving zinc acetate and phycocyanin in water to prepare a mixed solution; The mixed solution is added to a 2-methylimidazole aqueous solution, mixed and stirred, centrifuged, the precipitate is washed with water, and dispersed in water to obtain a nanoparticle dispersion; The nanoparticle dispersion, epigallocatechin gallate and manganese chloride are added into water, mixed and stirred, centrifuged, and the precipitate is washed with water and dispersed in water to prepare a metal organic framework material.

2. The method for preparing a metal organic framework material according to claim 1, characterized in that: The mass ratio of the zinc acetate to the phycocyanin is 5:1-2.

3. The method for preparing a metal organic framework material according to claim 1, characterized in that: The mass ratio of the phycocyanin to 2-methylimidazole is 1-2:0.

2.

4. The method for preparing a metal organic framework material according to claim 3, characterized in that: The concentration of the 2-methylimidazole aqueous solution is 90-110 mg / mL.

5. The method for preparing a metal organic framework material according to claim 1, characterized in that: The mass ratio of the epigallocatechin gallate to the manganese chloride is 2-3:

1.

6. A metal organic framework material, characterized in that The metal organic framework material is prepared by the preparation method of any one of claims 1 to 5.

7. An application of a metal organic framework material, characterized in that: The metal organic framework material according to claim 6 is used for in vitro antioxidant effect.

8. An application of a metal organic framework material, characterized in that: The metal-organic framework material according to claim 6 is used for the treatment of acute liver injury.

9. An application of a metal organic framework material, characterized in that: The metal organic framework material according to claim 6 is used for immune regulation.

Images